热门资讯> 正文
Edwards Lifesciences收购早期TMVR公司Innovalve
2024-07-15 21:27
- Edwards Lifesciences (NYSE:EW) has acquired Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement company, following its initial investment in 2017.
- The terms of the deal were not disclosed.
- The addition enhances its TMVR technologies to address unmet structural heart patient needs and support sustainable growth. Further, Innovalve will join the transcatheter mitral and tricuspid therapies (TMTT) product group.
- The acquisition is expected to close by the end of 2024.
- "Edwards’ SAPIEN M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025," said Edwards's corporate vice president, Daveen Chopra.
More on Edwards Lifesciences
- Edwards Lifesciences: Focus On The Heart
- Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
- Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
- BD to buy Edwards Life Critical Care unit for $4.2B in cash
- Citi upgrades Edwards, Tandem; cuts Nevro, Establishment Labs
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
